SPDR S&P Health Equip

LivaNova Executives to Speak at Goldman Sachs Global Healthcare Conference on June 8

Wolfe Research Lowers Teleflex 2029 Fiscal Year EPS Forecast to $14.19

STAAR Surgical released FY2026 Q1 earnings on May 13 After-Market (EST), actual revenue USD 93.52 M (forecast USD 78.72 M), actual EPS USD 0.1 (forecast USD 0.0285)

Needham Predicts TELA Earnings at $2.90 Per Share for Q1 2028

Wall Street Zen Downgrades Teleflex Stock Rating to Sell

Teleflex Reports Q1 2026 Earnings and Launches Share Repurchase Program

Lantheus released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 377.33 M (forecast USD 354.42 M), actual EPS USD 1.8 (forecast USD 0.9633)

Teleflex released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 548.26 M (forecast USD 537.59 M), actual EPS USD -0.1849 (forecast USD 0.3466)

Livanova released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 362.3 M (forecast USD 346.11 M), actual EPS USD 0.4 (forecast USD 0.6)

Avanos Medical released FY2026 Q1 earnings on May 5 (EST), actual revenue USD 182.2 M (forecast USD 170 M), actual EPS USD 0.1096

STAAR Surgical to Release FY2026 Q1 Earnings on May 13 After-Market EST, Forecast Revenue USD 78.72 M, EPS USD 0.0087

Integra LifeSciences released FY2026 Q1 earnings on May 5 Pre-Market EST, actual revenue USD 391.92 M (forecast USD 381.77 M), actual EPS USD -0.06 (forecast USD 0.05)

Glaukos COO Sold Company Stock

Glaukos releases investor presentation on glaucoma treatment pipeline

Novocure released FY2026 Q1 earnings on April 30 Pre-Market (EST), actual revenue USD 174.06 M (forecast USD 167.77 M), actual EPS USD -0.6231 (forecast USD -0.5128)

Lantheus to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 354.38 M, EPS USD 0.95

Teleflex to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 537.59 M, EPS USD 0.3466

Glaukos released FY2026 Q1 earnings on April 29 After-Market EST, actual revenue USD 150.57 M (forecast USD 137 M), actual EPS USD -0.3409 (forecast USD -0.38)

Livanova to release FY2026 Q1 earnings report on May 6 Pre-Market EST, forecast revenue USD 346.11 M, EPS USD 0.6

Axogen released FY2026 Q1 earnings on April 28 Pre-Market (EST), actual revenue USD 61.46 M (forecast USD 57.77 M), actual EPS USD -0.38 (forecast USD -0.3857)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results

Boston Scientific announced positive results from the FRACTURE trial for its SEISMIQ 4CE coronary IVL catheter, achieving primary safety and effectiveness goals in severe CAD patients. The trial showed a 93.3% freedom from major adverse cardiac events and a 93.7% procedural success rate. The device aims to improve stent placement by fracturing calcium buildup in arteries. Boston Scientific shares rose 2.27% to $57.19 following the announcement.

benzinga_article

Boston Scientific

iShares US Medical Devices

S&P 500

Stellantis NV

ATEC

IBBQ

Kirby McInerney LLP is investigating potential claims against Alphatec Holdings, Inc. regarding possible violations of federal securities laws. Following a disappointing first quarter report on May 5, 2026, where Alphatec's revenue fell short of expectations, the company's stock price dropped by approximately 32%. The investigation aims to determine if legal claims can be filed. Investors with information or interest are encouraged to contact the law firm.

MorningStar

Alphatec

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

ATEC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alphatec Holdings, Inc.

RPID

Rapid Micro Biosystems has raised approximately $8.9 million through an underwritten offering and an additional $140,000 from a concurrent purchase by certain directors and officers. The offering includes 3,581,000 shares and warrants, priced at $1.955 per share unit. Proceeds will be used for working capital and corporate purposes, with both transactions expected to close around May 20, 2026.

TradingView

Rapid Micro Biosystems

Toronto Dominion Bank

Rapid Micro Biosystems Raises $8.9M Net in Underwritten Offering, Adds $140K D&O Purchase

PODD

Insulet Corp. (PODD) shares rose 1.39% to $154.61 on Tuesday, despite a broader market decline, with the S&P 500 and Dow Jones falling 0.67% and 0.65%, respectively. The stock remains 56.43% below its 52-week high of $354.88. Compared to competitors, Insulet underperformed as Eli Lilly, DexCom, and Johnson & Johnson saw gains of 3.37%, 2.86%, and 0.47%.

MarketWatch Automated

Insulet

Dow Jones Industrial Average

Eli Lilly

DexCom

Johnson & Johnson

Insulet Corp. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

ORMP

Oramed Pharmaceuticals Inc. reported Q1 2026 results with $0 revenue and a net income of $38.31M, improving from a net loss of $(7.64) M in Q1 2025. Diluted EPS was $0.91, up from $(0.19) a year earlier. The company shifted to managing a medical technology portfolio, reduced R&D spending, and closed strategic transactions, including the Lifeward deal.

Oramed Pharma

Lifeward

Alpha Tau Medical

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary

CLDX

GLUC

CODX

ANVS

In Tuesday's after-market session, Co-Diagnostics shares surged 20.8% to $2.38, while Celldex Therapeutics rose 16.05% to $34.99. Other gainers included INVO Fertility (+13.28%) and Evaxion (+7.78%). Conversely, Annovis Bio fell 18.1% to $1.59, with GlucoTrack down 17.56%. Wellgistics Health and NexGel also saw declines of 10.72% and 10.41%, respectively. Most companies reported Q1 earnings recently.

Celldex Therap

Glucose Health, Inc.

Co-Diagnostics

Annovis Bio

iShares US Pharma

Health Care Select Sector SPDR

iShares Global Healthcare

INVO Fertility

Evaxion A/S

NeuroOne Medical Tech

Biorestorative Therapies

GlucoTrack

Wellgistics Health

Nexgel

AIM ImmunoTech

Icecure Medical

NEXGEL INC C/WTS 27/12/2026 (TO PUR COM)

AIM IMMUNOTECH INC

AIM ImmunoTech Inc.

12 Health Care Stocks Moving In Tuesday's After-Market Session

Mettler-Toledo International Inc. (MTD) shares fell 2.24% to $1,050.77 on Tuesday, underperforming compared to competitors like Emerson Electric Co. and Roper Technologies. The stock is currently 31.10% below its 52-week high of $1,525.17. Overall, the stock market saw declines, with the S&P 500 down 0.67%. Trading volume was significantly higher than the 50-day average.

Mettler Toledo

Emerson Electric

Roper Tech

Agilent Tech

Factset Research

Mettler-Toledo International Inc. Stock Underperforms Tuesday When Compared To Competitors

ResMed Inc. (RMD) shares rose 1.78% to $207.78 on Tuesday, outperforming a declining market where the S&P 500 fell 0.67% and the Dow Jones dropped 0.65%. This marks the second consecutive day of gains for ResMed, although it remains 29.28% below its 52-week high of $293.81 reached on August 22nd. Trading volume was 1.4 million, surpassing the 50-day average of 1.2 million.

Resmed

iShares US Healthcare Providers

SPDR S&P Health

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. Stock Rises Tuesday, Outperforms Market

Becton Dickinson & Co. (BDX) shares rose 3.23% to $146.95 on a challenging trading day for the market, outperforming competitors like Danaher Corp. and Medtronic PLC. The stock ended 21.56% below its 52-week high of $187.35, reached on February 24th. Trading volume was 3.9 million, surpassing the 50-day average of 2.9 million.

Becton Dickinson and

Danaher

Medtronic

Becton Dickinson & Co. Stock Outperforms Competitors On Strong Trading Day

LABU

SBIO

Medtronic PLC (MDT) shares rose 1.63% to $78.58 on a challenging trading day, outperforming the S&P 500 and Dow Jones, which fell 0.67% and 0.65%, respectively. This marks the second consecutive day of gains for Medtronic, though it remains 26.10% below its 52-week high of $106.33. Competitors like Johnson & Johnson, Danaher Corp., and Abbott Laboratories also saw gains. Trading volume for Medtronic was 11.9 million, surpassing its 50-day average of 8.9 million.

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Abbott Laboratories

Medtronic PLC Stock Outperforms Competitors On Strong Trading Day

Danaher Corp. (DHR) shares rose 1.94% to $167.04 on a challenging trading day for the market, outperforming competitors like Thermo Fisher, Abbott, and Medtronic. The stock is still 31.20% below its 52-week high of $242.80. Trading volume reached 5.7 million, surpassing the 50-day average of 4.6 million.

SPDR S&P Health Equip(XHE.US)